V
Valérie Vial
Publications - 12
Citations - 303
Valérie Vial is an academic researcher. The author has contributed to research in topics: Sunitinib & Cancer research. The author has an hindex of 5, co-authored 9 publications receiving 210 citations.
Papers
More filters
Journal ArticleDOI
The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5)
Yann Cormerais,Pierre André Massard,Milica Vučetić,Sandy Giuliano,Eric Tambutté,Jérôme Durivault,Valérie Vial,Hitoshi Endou,Michael F. Wempe,Scott K. Parks,Jacques Pouysségur +10 more
TL;DR: ASCT2KO reduces tumor growth by limiting AA import, but that this effect is independent of LAT1 activity, which indicates that the proposed functional coupling model of ASCT2 and LAT1 is not universal across different cancer types.
Journal ArticleDOI
Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas.
Maeva Dufies,Sandy Giuliano,Damien Ambrosetti,A. Claren,Papa Diogop Ndiaye,Michalis Mastri,Walid Moghrabi,Lindsay S. Cooley,Marc Ettaiche,Emmanuel Chamorey,Julien Parola,Valérie Vial,Marilena Lupu-Plesu,Jean-Christophe Bernhard,Alain Ravaud,Delphine Borchiellini,Jean Marc Ferrero,Andreas Bikfalvi,John M.L. Ebos,Khalid S.A. Khabar,Renaud Grépin,Gilles Pagès +21 more
TL;DR: It is found that sunitinib can stimulate vegfc gene transcription and increase VEGFC mRNA half-life and induced the development of lymphatic vessels, which may have contributed to the treatment failure.
Journal ArticleDOI
Disrupting glucose-6-phosphate isomerase fully suppresses the “Warburg effect” and activates OXPHOS with minimal impact on tumor growth except in hypoxia
Monique Meyenberg Cunha de Padua,Monique Meyenberg Cunha de Padua,Giulia Delodi,Milica Vučetić,Jérôme Durivault,Valérie Vial,Pascale Bayer,Guilhermina Rodrigues Noleto,Nathalie M. Mazure,Maša Ždralević,Jacques Pouysségur +10 more
TL;DR: The results indicate that exclusive use of oxidative metabolism has the capacity to provide metabolic precursors for biomass synthesis and fast growth and clearly indicate that metabolic cancer cell plasticity poses a strong limitation to anticancer strategies.
Journal ArticleDOI
Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5.
Sandy Giuliano,Maeva Dufies,Papa Diogop Ndiaye,Julien Viotti,Delphine Borchiellini,Julien Parola,Valérie Vial,Yann Cormerais,Mickaël Ohanna,Véronique Imbert,Emmanuel Chamorey,Nathalie Rioux-Leclercq,Ariel Savina,Jean-Marc Ferrero,Baharia Mograbi,Gilles Pagès +15 more
TL;DR: CXCL5 was identified as a biomarker of efficacy of lysosomotropic drugs, a potential asset for personalized medicine and correlated to shorter survival in RCC and to the most aggressive forms of breast cancers.
Journal ArticleDOI
AKT1 restricts the invasive capacity of head and neck carcinoma cells harboring a constitutively active PI3 kinase activity
Sanja Brolih,Scott K. Parks,Valérie Vial,Jérôme Durivault,Livio Mostosi,Jacques Pouysségur,Gilles Pagès,Vincent Picco +7 more
TL;DR: It is demonstrated that the alternative action of AKT1 on invasive properties of breast cancers can be extended to head and neck carcinomas, which exhibit constitutive activation of the PI3K/AKT pathway.